Mr. Massino: Senetek Plc is a British-based company. SENETEK trades as an ADR on NASDAQ. It was founded in 1983 by Nobel Prize laureates and it is and has always been a technology driven company. Unfortunately, previous management was unsuccessful in bringing this rich technology to market. Over the past two years, the current management has been highly successful in commercializing this technology and after 18 years, SENETEK realized its first full profitable year in 2001.
TWST: What is the technology that has come to the market finally?
Mr. Massino: The lead technology is a plant growth factor, Kinetin, a
cytokinin known to be very effective in alleviating the signs of the
aging process. Kinetin eliminates fine line wrinkles, coarse wrinkles,
rough skin, mottled hyperpigmentation and has the unique property of
improving moisture retention which is essential for maintaining healthy
skin and unlike its competitors has virtually no side effects. Kinetin
is endogenous to the human body and part of the DNA tissue repair
process. This technology has also demonstrated potential in the
treatment of psoriasis. There are additional applications for which we
are testing, and we may look to expand our patent position on our
cytokinin technology. Kinetin is the lead compound in SENETEK's rich
portfolio of skincare technology.
Tickers included in this excerpt: SNTK
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.